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ABSTRACT 
Viruses are accountable for numerous diseases that form an immense 
threat to public health worldwide. The capability of viruses to continuously 
adapt to a changing environment makes the discovery of new treatments for 
viral diseases crucial. Natural products play an important role in the discovery 
of new drug candidates, essentially as a source of lead compounds that can be 
chemically optimized to achieve improved drug properties, such as safety and 
efficacy.  
In natural product drug discovery, the marine environment offers 
outstanding potential to discover new compounds with interesting bioactive 
properties. Marine species and their unique metabolites are still only partly 
discovered, and at the same time, vulnerable marine environments are 
threatened by human activities through pollution, overexploitation and 
climate change. The protection of marine biodiversity and sustainable use of 
marine resources is therefore a vital part of the study of marine organisms and 
their metabolites. 
This dissertation focuses on studying the antiviral properties of marine-
derived compounds and their synthetic derivatives. The first part of this study 
covers screening of crude extracts from the Indian Ocean soft coral Sinularia 
kavarattiensis in a chikungunya virus replicon model followed by bioactivity-
guided isolation and further study of the purified compounds. This study led 
to the isolation of six known norcembranoid compounds and the isolation and 
characterization of one novel compound, kavaranolide. Two of the isolated 
compounds were moderately active in the chikungunya replicon model, but 
also showed cytotoxic properties.  
The second part of the research focuses on studying the antiviral potential 
of synthetic compounds inspired by the marine sponge-derived alkaloids 
clathrodin and oroidin. In the screening of a compound library of 157 
clathrodin and oroidin analogues in chikungunya virus and hepatitis C virus 
replicon models, four compounds were discovered to selectively inhibit the 
hepatitis C replicon with IC50-values ranging from 1.6 to 4.6 µM. Interaction 
with the cellular chaperone Hsp90 was proposed as the mechanism of action 
underlying the activity, and this hypothesis was supported by the results from 
molecular modelling and microscale thermophoresis interaction studies.  
Based on the study of clathrodin and oroidin analogues, 12 new 
compounds with a 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole structure were 
synthesized, in order to obtain improved binding to Hsp90 and improved 
  
antiviral properties. Three of the synthesized compounds showed improved 
binding to Hsp90 and specific inhibition in hepatitis C genotype 1b and 2a 
replicon models and moreover, inhibited the replication of full-length 
hepatitis C genotype 2a virus in a reporter virus RNA assay (IC50-values 0.03–
0.6 µM). As Hsp90 is a host protein utilized by the viral replication machinery, 
antiviral activity achieved through inhibition of Hsp90 could be an attractive 
strategy to combat resistant viral strains.  
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1 INTRODUCTION 
In an era where modern medicine has enabled remarkable control 
of infectious diseases worldwide, the global community continues to 
face severe challenges posed by longstanding, emerging and re-
emerging infectious diseases, many of which are caused by viruses.1 
Despite that hundreds of viral pathogens known to cause human 
disease have been identified, approved antiviral therapies are 
available only for few.2 Researchers are challenged by the outstanding 
ability of pathogens to adapt to an ever-changing environment, 
leading to drug resistance and changing patterns in spread of diseases. 
The utilization of natural products in drug discovery keeps playing 
an important role in the development and discovery of new 
pharmaceuticals.3 In natural product drug discovery, marine natural 
products have gained increasing interest over the past decades.4 
Oceans cover a majority of the earth’s surface, but only part of the 
massive biodiversity that these unique environments represent have 
been studied.5 Even though our understanding of the expanse of 
marine species and the richness of underwater habitats is increasing, 
marine flora and fauna is threatened by multiple factors tracing back 
to human activities. Protection activities fail to keep up with the 
emerging threats such as microplastic pollution and alarming 
outcomes of global climate change, most importantly sea level rise, 
acidification, stratification, habitat destruction and changes in ocean 
circulation.6-8  
While some natural products used in medicine are isolated from 
their natural origin or produced through full or partial chemical 
synthesis, natural products are especially important as a source of 
chemical leads.3 The drug properties of these lead compounds can be 
chemically optimized to improve aspects such as efficacy, safety and 
pharmacokinetic profile. 
This thesis focuses on the discovery of compounds with antiviral 
activity based on marine natural products. By using viral replicon-
based cell models, diverse sets of compounds can be screened for their 
potential to interfere with the replication of the target virus. The use 
of replicon models provides a safe, efficient and user-friendly means 
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for identification of compounds and marine-derived compound 
mixtures with interesting bioactive properties. In this work, the 
results of the cell-based replicon screens were utilized as a base for 
bioactivity-guided compound purification and characterization, 
successful chemical optimization of the identified hit compounds, 
characterization of hit compound properties and analysis of the 
potential mechanism of action. 
  12 
2 REVIEW OF THE LITERATURE 
2.1 Marine natural products in drug 
discovery 
A majority of the planet’s surface is covered by water, and oceans 
represent an enormous biodiversity that holds outstanding 
opportunities to find unique pharmacologically active substances.4,9 
The biodiversity of the deep sea is among the highest on the planet, 
yet it has been estimated that less than 5% of the deep sea has been 
explored and less than 0.01% of the deep sea floor has been studied in 
detail.5  This suggests that much of the potential of marine organisms 
as sources of new drugs still remains undiscovered. 
The use of marine-derived products has been present in traditional 
medicine in China and Japan for centuries, but the systematic 
exploring of marine sources for new drug candidates began in the 
1960’s and has raised interest in academia and the pharmaceutical 
industry ever since.4 As a result of intensive research in the area, 
hundreds of new marine-derived compounds are described every 
year.10 These compounds often represent unique and diverse 
chemotypes with interesting biological activities.10,11 
During the first decades of marine drug discovery, a great 
proportion of the new compounds isolated from marine organisms 
originated from marine invertebrates – up to 2008, approximately 
75% of marine bioactive compounds were isolated from marine 
invertebrate phyla Porifera and Coelenterate.12 The interest in 
bioactive compounds produced by marine micro-organisms is, 
however, steadily increasing. A recent review by Carroll and 
coworkers13 shows that since 2014, the number of new marine 
compounds isolated from marine microbes has exceeded the number 
of compounds isolated from invertebrates. Figure 1 visualizes this 
ongoing change in marine drug discovery. The number of new 
compounds from other sources than micro-organisms and 
invertebrates is comparably low and has stayed somewhat stable over 
the past years.13  
  13 
It is also becoming evident that numerous bioactive natural 
products are not produced by the organism from which their isolation 
was originally described, but in fact by microbes living in symbiotic 
relationships with the eukaryotic host organism.14 An excellent 
example of such a compound is the marine-derived anticancer agent 
trabectedin (ET-743, Yondelis®) from the Caribbean mangrove 
tunicate Ecteinascidia turbinate which, based on genome sequencing 
data, is suggested to be a product of a symbiotic micro-organism of the 
tunicate.15 
 
 
Figure 1.  Sources of new marine compounds from year 2012 to 
2017 (adapted from Carroll et al. 2019 ©The Royal 
Society of Chemistry). 13 
 
When analysing the chemical structures of the compounds isolated 
from marine sources, alkaloids and terpenes are the most abundant 
compound classes representing 23.66% and 22.46%, respectively, of 
the marine-derived compounds described in literature up to year 
2012.10 They are followed by ethers and ketals (11.89%), sterides 
(9.76%), lactones (9.68%), peptides (8.80%) and hydroxybenzenes 
and chinones (6.99%).10  
Anticancer drug development has historically been the core of 
marine drug discovery, which mainly has its roots in the allocation of 
research funding that has favored anticancer research over other 
targets.4,10 A review of biologically active compounds derived from 
marine sources between years 1985 and 2012 shows that more than 
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half of the new compounds were described to possess anticancer 
activity (Figure 2).10 Other bioactive properties reported for marine-
derived compounds are antibacterial, antifungal, antiviral, pest 
resistance, prevention of cardiovascular disease and neuroprotection 
(Figure 2).  
Figure 2.  The proportion and amount of different bioactivity 
classes in marine-derived compounds discovered 
between years 1985 and 2012. *PN/NT: protection of 
neurons/neurotoxicity. **PHVD: prevention of heart 
and vascular disease. Figure adapted from Hu et al. 
2015 © MDPI.10 
 
The effort put on anticancer drug discovery over the past decades 
is also reflected by the fact that out of 11 marine-derived compounds 
approved for clinical use, 5 are anticancer drugs (Table 1).11 The 
marine-derived drugs approved for clinical use represent a plethora of 
structurally and chemically diverse compounds. It shall also be noted, 
that not all compounds presented in Table 1 are registered as drugs, 
but as medical devices. For instance, the antiviral compound 
Carragelose® is marketed as a medical device.  
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Table 1.  Marine-derived drugs and medical devices in clinical 
use. 
Drug and 
trade name 
Chemical 
class 
Indication Source Refe-
rence 
Brentuximab 
vedotin  
(Adcetris®)  
Antibody-drug-
conjugate 
consisting of 
monoclonal 
antibody cAC10 
and cytotoxic 
agent MMAE 
Anticancer The cytotoxic 
agent MMAE is 
a synthetic 
derivative of 
dolastatin 10, a 
pseudopeptide 
from mollusc 
Dorabella 
auricularia 
[16] 
Cytarabine, 
Ara-C 
(Cytosar-
U®) 
Nucleoside Anticancer Synthetic 
derivative 
inspired by the 
arabinose-
containing 
nucleosides 
spongothymidin
e and 
spongouridine 
from the 
Caribbean 
sponge Tethya 
crypta 
[4] 
Eribulin 
mesylate 
(Halaven®) 
Macrocyclic 
ketone  
Anticancer Synthetic 
derivative of 
halichondrin B 
originally 
isolated from 
marine sponge 
Halichondria 
okadai 
[17] 
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Drug and 
trade name 
Chemical 
class 
Indication Source Refe-
rence 
Ethyl 
eicosapentae
noic acid 
(Vascepa®) 
Fatty acid Anti-
hypertriglyceri
demia 
Fish oil-derived 
product 
[11] 
Iota-
carrageenan 
(Carragelose
®) 
Sulphated 
galactose 
polymer 
Antiviral Rhodophyceae 
seaweeds 
[18] 
Omega-3-
acid ethyl 
esters 
(Lovaza®) 
Fatty acid Anti-
hypertriglyceri
demia 
Fish oil-derived 
product 
[11] 
Omega-3 
carboxylic 
acids 
(Epanova®) 
Fatty acid Anti-
hypertriglyceri
demia 
Fish oil-derived 
product 
[11] 
Polatuzumab 
vedotin 
(Polivy®) 
Antibody-drug-
conjugate 
consisting of 
anti-CD79 
monoclonal 
antibody and 
cytotoxic agent 
MMAE 
Anticancer The cytotoxic 
agent MMAE is 
a synthetic 
derivative of 
dolastatin 10, a 
pseudopeptide 
from mollusc 
Dorabella 
auricularia 
[4,19] 
Trabectedin, 
ET-743 
(Yondelis®) 
Tetrahydro-
isoquinoline 
alkaloid 
Anticancer Mangrove 
tunicate 
Ecteinascidia 
turbinata 
(Symbiotic 
micro-organism 
Candidatus 
[15,20] 
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Drug and 
trade name 
Chemical 
class 
Indication Source Refe-
rence 
Endoecteina-
scidia 
frumentensis) 
Vidarabine, 
Ara-A (Vira-
A®) 
Nucleoside Antiviral Synthetic 
analogue of 
spongouridine 
isolated from 
Caribbean 
sponge Tethya 
crypta 
[21] 
Ziconotide 
(Prialt®) 
Cyclic peptide Analgesic Synthetic 
version of 
peptidic 
neurotoxin 
produced by 
marine snail 
Conus magus  
[22] 
 
As shown in Table 1, nearly all clinically approved compounds 
result from chemical optimization of a marine lead structure.  Indeed, 
natural products form only a small portion (6%) of new chemical 
entities introduced to the  clinic, as synthetic derivatives of natural 
products or compounds inspired by natural products, are 
predominant.3 In addition to currently approved compounds, several 
marine-derived compounds are being investigated in clinical trials.4,11 
2.2 Marine-derived antivirals 
This section discusses the antiviral compounds of marine origin 
that have been developed into clinical use. Additionally, an overview 
of the marine-derived antivirals bryostatins and griffithsin with 
potential for future clinical use in treatment and prevention of viral 
diseases is presented. 
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2.2.1 Vidarabine 
Vidarabine (Ara-A; Vira-A®, Figure 3), a synthetic analogue of the 
nucleoside spongouridine, was the first marine-derived antiviral 
agent taken into clinical use.21 The isolation of spongouridine from the 
Caribbean sponge Tethya crypta was reported by Bergmann and 
Feeney already in 1951.23 The peculiarity of spongouridine and 
concomitantly isolated spongothymidine is that the sugar unit in these 
nucleosides is arabinose instead of the more commonly occurring 
ribose. Vidarabine is active against herpes simplex virus and varicella-
zoster viruses, although its use has largely ceased due to availability of 
more potent antivirals, such as acyclovir.21,24 
 
Figure 3.  Structure of vidarabine. 
2.2.2 Iota-carrageenan 
Iota-carrageenan (Figure 4) is derived from red algae 
(Rhodophyceae).18 It is a sulphated galactose polymer commonly used 
in nutritional preparations and topical products18, marketed as an 
over-the-counter product under trade name Carragelose®.25 
Carrageenan polymers are classified into Iota-, Kappa- and Lambda-
polymers depending on the amount and location of the sulphate 
moieties in the polymer structure.26  In clinical evaluation of Iota-
carrageenan nasal spray, a 0.12% saline solution administered three 
times a day upon early onset of common cold symptoms reduced the 
symptoms, the viral load of nasal lavages and levels of pro-
inflammatory mediators.18 Administration of Iota-carrageenan nasal 
spray has been shown to reduce the duration of disease and reduce 
relapses of common cold caused by human rhinovirus, human 
coronavirus and influenza A virus.27 
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Figure 4.  Structure of iota-carrageenan. 
2.2.3 Bryostatins 
Bryostatins are a class of more than 20 naturally occurring 
macrolidic cytotoxins originally isolated from marine bryozoan 
species Bugula neritina.4 Bryostatins occur in B. neritina in very low 
amounts, and it is likely that their actual producer is an uncultivated 
bacterial symbiont of the invertebrate.28 Total synthesis for bryostatin 
1 (Figure 5) has been developed and synthetic ring-expanded 
derivatives have also been reported.29-31 Bryostatins and their 
analogues act mainly through modulation of protein kinase C activity 
and have been studied extensively as potential drugs against 
numerous targets, most notably Alzheimer’s disease, cancer and 
HIV.4,32 In a clinical trial in HIV-infected patients, bryostatin 1 was 
well tolerated but did not affect protein kinase C activity or 
transcription of latent HIV.33 
 
Figure 5.  Structure of bryostatin 1. 
 
Based on the assumption that only part of the bryostatin 1 
structural moieties are accountable for its biological activity, a 
pharmacophore model has been used to guide the synthesis of 
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simplified bryostatin analogues, “bryologs” that in vitro induce the 
activation of latent HIV.34 The reversion of HIV from latency while 
administering antiretroviral therapy would allow eradication of the 
reservoir cells. 34 An in vivo study conducted in humanized mice 
showed that the bryostatin analog SUW133 was better tolerated than 
naturally occurring bryostatin 1 and it potently induced HIV 
expression from latency.35 Besides HIV, bryostatin analogs might be 
promising candidates in the treatment of other latency-exhibiting 
viral infections, such as infection by herpes simplex viruses.4 
2.2.4 Griffithsin 
Griffithsin is a protein isolated from red alga Griffithsia sp. that 
shows interesting potential for drug development against numeral 
viral infections, including HIV, SARS-CoV and other related 
Coronaviridae viruses, HCV, HPV and JEV.36 Griffithsin acts as a viral 
entry inhibitor that prevents the cell-to-cell transmission of the 
virus.36,37 Scalable manufacturing of griffithsin has been achieved in 
tobacco plants through the use of a tobacco mosaic virus vector 
expressing the protein.37   
In the study of plant-produced griffithsin on human cervical 
explants, griffithsin potently prevented infection of the explants by 
HIV-1.37 In the same study, griffithsin was shown to be non-irritant 
and non-inflammatory in human cervical explants and in an in vivo 
rabbit model, while showing no detectable mitogenic activity on 
human peripheral mononuclear cells.37 The beneficial safety profile of 
griffithsin has been further demonstrated in study of its effects on the 
rectal mucosal microbiome and proteome in rhesus macaques.38 
Furthermore, the clinical safety of vaginally and rectally administered 
griffithsin is currently being studied.39,40 
2.3 Hepatitis C virus (HCV) 
The World Health Organization estimates that 71 million people 
globally are infected with hepatitis C virus (HCV) and that a significant 
proportion of infected patients develop liver cirrhosis or liver cancer.41 
In 2016, HCV and its associated diseases led to the death of 
approximately 390 000 people.41 HCV is transmitted by exposure to 
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contaminated blood either percutaneously, from mother to infant, or 
by sexual intercourse.42 
2.3.1 HCV classification and characteristics 
HCV is a positive-strand enveloped RNA virus that belongs to the 
genus Hepacivirus in the Flaviviridae family.42 HCV is a genetically 
heterogeneous group of viruses classified into seven genotypes that 
are distinguished by differences in genome, geographical distribution, 
progression of disease and treatment response.43 Furthermore, the 
different genotypes are divided into subtypes. On the nucleotide level, 
the HCV genotypes differ from each other by 31-33%, whereas 
subtypes show 20-25% divergence.44 Also intergenotypic and 
intersubtype HCV genomes do occur.45,46 
The HCV virion is approximately 45-75 nm in size and consists of 
the positive-strand RNA, the core protein that forms the viral 
nucleocapsid and two envelope glycoproteins, E1 and E2.47,48 The RNA 
genome contains almost 10 000 nucleotides and consists of a 5’ non-
translated region that acts as internal ribosome entry site (IRES), an 
open-reading frame that encodes the structural and non-structural 
proteins and a 3’ non-translated region.47,49 The structural proteins 
consist of the core protein, the envelope glycoproteins E1 and E2 and 
viroporin p7, which is essential for production and release of new 
infectious virus particles from infected cells.48,50 The six non-
structural proteins (NS) responsible for the viral replication process 
are the NS2-3 protease, the NS3 serine protease, the NS4A 
polypeptide, the NS4B and NS5A proteins and the NS5B RNA-
dependent RNA polymerase.47 
2.3.2 HCV replication and host response 
HCV replication mainly takes place in the liver parenchymal cells, 
the hepatocytes, which the virus enters through receptor-mediated 
endocytosis.48 The envelope glycoproteins E1 and E2, which together 
are suggested to form a disulfide-bridge stabilized heterodimer 
mediate the receptor binding and cellular entry of the virus particle.48 
After cell entry the translation of the genomic RNA is directly initiated 
with mediation of the IRES.49 The HCV half-life in the body of the 
infected individual is less than 3 hours and the replication process is 
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highly efficient with production and clearance rate of 1012 viral 
particles per day.51 Typically, the acute phase of HCV infection is 
asymptomatic, and without treatment, can lead to later onset of liver 
complications such as cirrhosis and hepatocellular carcinoma.52 
The immune response to HCV infection involves both innate and 
adaptive immunity and affects the progression of the infection in the 
acute and long-term phase.53 Even within one host, HCV exists as a 
genetically diverse viral population, which makes tackling the virus 
challenging for the innate immune system and may lead to 
establishment of widespread infection before the innate immune 
response is activated.53,54 Despite this, approximately one out of four 
HCV patients spontaneously clear the virus, with a higher likelihood 
for viral clearance in female patients compared to men.55 
2.3.3 Model systems in HCV research 
The study of the HCV life cycle and potential replication inhibitors 
took a leap forward in 1999 upon creation of a cell culture system 
utilizing Huh-7 hepatoma cells that express a subgenomic HCV 
replicon and a selectable marker.56 In 2005, complete in vitro 
replication in cell culture of HCV genotype 2a, cloned from an 
individual with fulminant hepatitis, was achieved.57,58 The secreted 
virus, infectious for Huh-7 cells, was shown to be neutralized by 
antibodies and immunoglobulins from patients chronically infected 
with HCV.57 Furthermore, the use of HCV pseudoparticles, related 
viruses such as the bovine viral diarrhoea virus, as well as chimpanzee 
and mouse animal models have been utilized in the study of 
progression of HCV infection, viral replication and host-HCV 
interactions.47 
2.3.4 Current HCV treatment 
The treatment options for HCV infection have evolved rapidly in 
recent years upon the introduction of direct-acting antiviral (DAA) 
therapies.59 The aim of HCV treatment today is to cure the infection, 
which means achieving a sustained virological response (SVR) defined 
as undetectable HCV RNA 12 weeks or 24 weeks after completing 
treatment.60  
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Prior to the introduction of DAAs, HCV treatment was limited to 
interferon therapy, often applied in combination with the antiviral 
agent ribavirin61, a nucleoside analogue assumed to have multiple 
modes of action: mainly direct inhibition of HCV replication, 
inhibition of host inosine monophosphate dehydrogenase enzyme, 
induction of viral mutagenesis and induction of host immune 
response.62 Interferon therapy comes with the risk of adverse effects 
such as bone-marrow depression, flu-like symptoms, 
neuropsychiatric conditions and autoimmune disorders, whereas 
ribavirin treatment is associated with hemolytic anemia.63 These 
issues led to problems with adherence to therapy as well as premature 
therapy withdrawals. 
The first DAAs taken into clinical use in 2011 were NS3 protease 
inhibitors boceprevir and telaprevir that were used in triple therapy 
together with pegylated interferon alpha and ribavirin.64,65 The 
introduction of these DAAs to the treatment regimen improved the 
treatment outcomes of HCV as measured by the SVR, which was 
approximately 75% in patients infected with HCV genotype 1 and 
treated with triple therapy containing either boceprevir or 
telaprevir.64,65 After the introduction of the first NS3 protease 
inhibitors, numerous DAAs have been developed and many are in 
clinical trials, with treatment outcomes exceeding 95% SVR.59,66 The 
main targets in development of DAAs are HCV NS3, NS5A and 
NS5B.66  
Due to the fast and error-prone replication of HCV, resistance 
development towards DAAs is a critical issue in treatment of the virus 
despite the development of new efficient antivirals.66,67 To prevent 
occurrence of resistant mutations, most of the current treatment 
regimens involve dual or triple therapy combining DAAs with 
different mechanisms of action.66 An overview of the DAAs and their 
combinations recommended for the treatment of HCV in the clinical 
practice guideline of the European Association for the Study of the 
Liver,60 is provided in Table 2. As reflected by Table 2, the NS5B 
polymerase inhibitor sofosbuvir is nowadays the cornerstone of HCV 
treatment.60 The current treatment options enable achieving a SVR 
that corresponds to cure of the infection with low risk of relapse. Long-
term follow-up studies show that definitive cure of HCV is achievable 
in a vast majority of cases.60 
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Table 2.  Drugs and drug combinations recommended for 
clinical treatment of HCV in Europe.60,68-75 
Drug or drug combination Mechanism of action 
Sofosbuvir NS5B polymerase inhibitor  
Sofosbuvir/ 
velpatasvir 
NS5B polymerase inhibitor/ 
NS5A inhibitor 
Sofosbuvir/ 
velpatasvir/ 
voxilaprevir 
NS5B polymerase inhibitor/ 
NS5A inhibitor/ 
NS3-NS4A protease inhibitor 
Glecaprevir/ 
pibrentasvir 
NS3-NS4A protease inhibitor/ 
NS5A inhibitor 
Sofosbuvir/ 
ledipasvir 
NS5B polymerase inhibitor/ 
NS5A inhibitor 
Paritaprevir/ 
ombitasvir/ 
ritonavir 
NS3-NS4A protease inhibitor/ 
NS5A inhibitor/ 
HIV protease inhibitor 
Dasabuvir NS5B polymerase inhibitor 
Grazoprevir/ 
elbasvir 
NS3-NS4A protease inhibitor / 
NS5A inhibitor 
2.4 Chikungunya virus (CHIKV) 
Chikungunya virus (CHIKV) causes a disease called chikungunya 
fever for which the characteristic acute symptoms are high fever, joint 
pain, myalgia, nausea, headache and rash.76-78 Besides the symptoms 
caused by acute infection, chikungunya fever typically leads to a 
chronic disease stage with relapsing rheumatic manifestations that 
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can persist for months or even years after the initial CHIKV 
infection.79,80 Asymptomatic infections have also been reported and 
estimated to occur in approximately 15% of the infected individuals.81 
Herein, the features of the virus, its spread and applied strategies for 
antiviral drug development against CHIKV are discussed. As vaccine 
development is not in the scope of this thesis, the vaccine strategies 
are not included. 
2.4.1 CHIKV classification and characteristics 
CHIKV is classified as an alphavirus and it belongs to the family 
Togaviridae.82 The alphaviruses are positive-strand RNA viruses 
spread by arthropods that characteristically use vertebrates, including 
humans, as hosts. Alphaviruses are further classified into Old World 
and New World alphaviruses based on geographical distribution and 
infectious properties and, based on antigenic classification, into at 
least eight different categories.82,83 CHIKV is an Old World alphavirus 
that belongs to the Semliki Forest complex.84 
The alphavirus particles are 60-70 nm in diameter and their 
genetic material is protected by a capsid formed by a single protein.82 
The alphavirus nucleocapsid is surrounded by a lipid envelope that 
contains two virus-encoded glycoprotein components, E1 and E2, 
which play an essential role in the attachment and entry of the virus 
to its host cell. In addition, a third surface protein E3, which has the 
same precursor as E2, is present on the virion surface.85  
The alphavirus genome is a single-stranded positive-sense RNA 
composed of 11 000 to 12 000 nucleotides with two open-reading 
frames and encodes for the structural and non-structural proteins.82 
The non-structural protein open-reading frame is located at the 5’ end 
of the genome and encodes for four proteins that the virus uses for 
transcription and replication of viral RNA, polyprotein cleavage and 
RNA capping.82,86 The structural open-reading frame encodes for the 
precursors of the three envelope and capsid proteins.86 nsP1 is 
responsible for negative-strand RNA synthesis and RNA capping, 
nsP2 has NTPase, RNA helicase, RNA triphosphatase and thiol 
protease activities, nsP3 participates in RNA synthesis and nsP4 is a 
RNA-dependent RNA-polymerase.86 
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2.4.2 CHIKV transmission, replication and 
epidemics 
CHIKV is transmitted to the vertebrate host through the bite of an 
infected mosquito, most commonly belonging to the genus Aedes.87 
The alphavirus virions enter their host cell via receptor-mediated 
endocytosis, after which the virion, surrounded by an endosome, is 
released to the cytoplasm.84 Following this, the viral nucleocapsid 
binds to the host ribosomes and the viral genomic RNA is released for 
translation.84 After infection through a mosquito bite, CHIKV 
replicates in the skin fibroblast cells and spreads to the liver and 
joints.88-90 
A CHIKV epidemics resulting in massive spread of the virus broke 
out in 2005 as the result of a single mutation in the viral genome.91 
The mutation enabled the adaptation of the virus to the geographically 
widespread mosquito species Aedes albopictus, which is a common 
vector for arthropod-borne diseases.92 Due to adaptation to the A. 
albopictus vector, CHIKV epidemics are no longer restricted to 
tropical areas, but have been reported in regions with temperate 
climate, such as Italy and the south-eastern parts of France.93-95 In the 
Americas, CHIKV was first reported in 2013, and has since then 
spread into all Central American countries, northern Mexico and most 
of South America.96-98 
2.4.3 Drug development strategies against CHIKV 
The current treatment of chikungunya fever is symptomatic, 
including the use of analgesics, anti-inflammatory agents including 
corticosteroids, and sometimes amitriptyline or gabapentin, in case 
the patient suffers from neuropathic pain.99-100 Disease-modifying 
anti-rheumatic therapy such as methotrexate may be initiated at 
earliest 8 weeks after the acute phase of the disease.100 Like in the 
acute phase, non-steroidal anti-inflammatory drugs and 
corticosteroids may also be used in the chronic phase. Since the 
massive epidemic that started in 2005, there has been a growing 
interest in studying vaccines and antivirals that could be used in 
prevention and treatment of CHIKV infection.101  
An advantageous treatment option would be the use of an antiviral 
that has already been approved for clinical use in another indication, 
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as the safety profile of such an agent would already be well-
characterized. The antiviral agent ribavirin, a guanosine analogue, has 
been shown to be effective against CHIKV in vitro in combination with 
interferon-alpha.102,103 In another study ribavirin was administered in 
combination with the tetracycline antibiotic doxycycline in mice 
animal models, and effective inhibition of CHIKV replication together 
with attenuated infectivity was achieved.104 Despite the rather 
promising results achieved in vitro using interferon against CHIKV, 
the success in clinical use of interferons against other viruses than 
HCV has been modest.105  
The nucleobase mimetic favipiravir, originally discovered as an 
influenza A replication inhibitor, was shown to inhibit replication of 
laboratory strains and clinical isolates of CHIKV as well as other 
related alphaviruses in vitro.106 Favipiravir also reduced CHIKV-
induced disease in a mouse model compared to placebo treatment. 
Various natural product-derived compounds have been studied in 
the search for potential anti-CHIKV activity. The natural product 
curcumin has been demonstrated to be active against CHIKV through 
blocking cell entry in vitro.107,108 Berberin, a-plant-derived alkaloid 
compound, has been shown to inhibit CHIKV replication dose-
dependently in vitro, to possess broad antiviral activity against related 
alphaviruses Semliki forest virus and Sindbis virus and to reduce 
CHIKV-induced inflammatory disease in vivo in a mouse model.109,110 
An alternative approach for identifying potential CHIKV inhibitors 
is application of computer-aided (in silico) techniques in screening of 
compound libraries, often accompanied by synthetic chemistry to 
optimize identified hits.101 Such techniques have been applied 
successfully to identify compounds that target the CHIKV nsP2, for 
which the three-dimensional structure is known.111,112 Furthermore, 
automated high-throughput screening can be applied to efficient 
studying of large compound libraries against CHIKV.113 
Targeting the CHIKV viral genome directly has been studied in 
applications using small interfering RNAs, microRNAs and small 
hairpin RNAs.114-117 In a study where four artificial microRNAs were 
designed to target different regions of the CHIKV genome, the 
concomitant use of these microRNAs resulted in over 99% inhibition 
of CHIKV in a plaque reduction assay in Vero cells.117 In another study, 
a plasmid-based small hairpin RNA, targeted for CHIKV capsid 
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structural protein E1 and nsP1 genes, inhibited CHIKV replication in 
cell culture and in a mouse model of CHIKV infection in vivo.115 
Neutralizing antibodies targeting the structural E2 protein of 
CHIKV have been shown to protect mice from infection in vivo.118,119 
Interestingly, a mouse monoclonal antibody targeted for structural 
protein E1 showed reduction of the virus progeny in cells infected with 
CHIKV whilst the virus replication was not affected.120 The further 
observation that the virus accumulates in the cells led the researchers 
to suggest the inhibition of virus release as the mechanism of action. 
Furthermore, monoclonal antibodies in combination with disease-
modifying antirheumatic drug abatacept efficiently controlled foot 
swelling and reduced the levels of inflammation markers in a disease 
mouse model.121 
Another interesting approach to CHIKV drug development is 
targeting the host cell factors and pathways that interfere with the life 
cycle of the virus. Protein kinase C is a family of kinases that play many 
roles in cellular functions and has been proposed as a potential host 
target in inhibition of CHIKV replication by Abdelnabi and 
coworkers.122 Prostatin, a protein kinase C activator, was shown to 
dose-dependently reduce the production of infectious CHIKV 
particles and halter the accumulation of viral proteins in human skin 
fibroblast cells.122  
Targeting polyamines, small molecules required for diverse 
cellular processes has been suggested as another possible method to 
inhibit CHIKV replication through a non-viral target.123 CHIKV 
replication has been shown to be regulated by depletion of the 
polyamines spermidine and spermine as the virus requires these 
polyamines for genome transcription and translation. 
2.5 Inhibition of Hsp90 as an antiviral 
strategy 
This section reviews the role of Hsp90 in the viral life cycle with 
focus on HCV and CHIKV, which are used in the antiviral screening 
described in this work.  
Heat shock protein 90 (Hsp90) is a family of molecular 
chaperones and one of the most common protein types encountered 
in cytoplasm with many essential cellular functions.124 The vital role 
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of chaperones is explained by their ability to support other proteins in 
the cell through stabilizing otherwise unstable protein conformers and 
facilitating their function.125 Hsp90 is a highly conserved protein 
found in organisms from bacteria to mammals.124 Hsp90 exists in the 
cytoplasm in two main forms, constitutively expressed Hsp90β and 
the inducible form Hsp90α.126 Cellular stress causes induction in the 
transcription of Hsp90 leading to approximately a doubled expression 
rate in cells that are subject to stress.124  
Viruses rely on the replication machinery of the host cell, and 
therefore viruses are as dependent on the chaperone functions as are 
the host cell proteins.127 Numerous viral proteins are client proteins of 
Hsp90, and also some host factors participating in the progression of 
viral infection require Hsp90 for their processing.128 Hsp90-
dependent processes in the life cycle of viruses are mainly the entry of 
the virus to the host cell, intracellular trafficking, the expression of 
viral genes, genome replication, viral protein stabilization, the 
maturation of the virion and viral infectivity.128 
Hsp90 plays several roles that are essential for the lifecycle of HCV 
in the infected cell. An overview of the Hsp90 functions relevant for 
successful HCV propagation is presented in Table 3. As demonstrated 
in Table 3, Hsp90 has been identified to participate in HCV replication 
through interaction with NS3 and NS5.129-135 Furthermore, Hsp90 
affects the expression of viral genes through interaction with the host 
cell protein argonaute2.136 Inhibiting the function of Hsp90 thus has 
impact on several aspects of the progression of HCV infection in the 
host cell. 
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Table 3.  The roles of Hsp90 in the HCV lifecycle. 
Hsp90-
dependent 
process 
Hsp90 
client 
protein 
Role of Hsp90 Reference 
Genome 
replication 
NS3 Cleavage at NS2/3 
junction, function of 
NS3 
[129, 134,135] 
Genome 
replication 
NS5 Function of NS5,  
replication complex 
formation/genome 
replication 
[130-133] 
Stabilization 
of viral 
proteins 
NS3 Stabilization of NS3 [134] 
Expression of 
viral genes 
Host cell 
argonaute2 
Hsp90 stabilizes 
argonaute protein 2. 
Argonaute proteins bind 
small RNA components 
and coordinate 
expression of genes 
through interaction with 
other proteins. 
[136] 
 
The functions of Hsp90 in the life cycle of CHIKV have not been 
extensively studied, however, there is evidence that Hsp90 
participates in CHIKV propagation. Rathore and co-workers 
demonstrated that CHIKV nsP3 and nsP4 are likely to be Hsp90 client 
proteins and that CHIKV replication in cell culture is disrupted by 
siRNA-mediated silencing of Hsp90 transcripts.137 In addition, Hsp90 
inhibitors were shown to reduce viral titres and reduce inflammation 
in vivo in a murine CHIKV model. Interestingly, both Hsp90α and 
Hsp90β isoforms interact with CHIKV non-structural proteins. In 
another study, Das and coworkers showed through 
immunoprecipitation studies that Hsp90 interacts with CHIKV nsP2 
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and that the translation of viral and cellular mRNA may be facilitated 
through a Hsp90-associated signaling pathway, suggesting that 
Hsp90 is required for the replication and production of viruses in 
CHIKV-infected cells.138 
The N-terminal ATP-binding domain of Hsp90 is the target site of 
most Hsp90 inhibitors, such as 17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG) and 17-N-allylamino-17-
demethoxy-geldanamycin (17-AAG), which are commonly used as 
model compounds for Hsp90 inhibition.139 Binding of compounds to 
this domain results in malformation and/or degradation of the Hsp90 
client protein. Inhibitors targeting the C-terminal and middle regions 
of Hsp90 have also been described but are less common.  
Despite the prospects of developing antivirals targeting Hsp90, the 
largest efforts have so far been put in developing Hsp90 inhibitors for 
the treatment of cancer. The role of Hsp90 in the life cycle of cancer 
cells is well characterized, and since the discovery of the first Hsp90 
inhibitor in 1994, intensive research has been ongoing in order to 
develop anticancer agents that act through Hsp90 inhibition.140  
The clinical development of Hsp90 inhibitors has been hindered 
by the lack of target specificity, off-target effects and insufficient 
validation for the mechanism of action.141 The in vivo toxicity 
hampering the clinical development of Hsp90 inhibitors is likely 
related to the abundance, multiple roles and numerous client proteins 
of Hsp90 in cells, which makes targeting specific viruses and 
controlling cytotoxicity main priorities in developing Hsp90-targeted 
antivirals.128 
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3 AIMS OF THE STUDY 
This study aimed to identify novel marine-derived antiviral 
compounds, both by studying compounds isolated from marine 
organisms (I) and by exploring synthetic compounds inspired by 
marine lead structures (II, III). The aim was first to evaluate antiviral 
potential through simple and efficient primary screening methods to 
identify hit compounds.  Moreover, the study aimed to characterize 
the hit compounds from the primary screening phase to evaluate the 
properties relevant for further drug development potential, such as 
specificity, toxicity and mode of action. 
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4 MATERIALS AND METHODS 
4.1 Studied marine-derived material  
The study covered screening for antiviral compounds from marine 
sources and included the study of both marine extracts and 
compounds isolated thereof as well as synthetic compounds inspired 
by marine lead structures. In publications I – III, the following types 
of samples were studied: 
• (I): Crude methanol extract of Indian Ocean soft coral S. 
kavarattiensis, chloroform- and ethyl acetate-enriched 
extracts and 7 purified compounds isolated from the 
chloroform-enriched extract. Soft coral species S. 
kavarattiensis was collected off the coast of Rameshwaram, 
Tamil Nadu, India (Latitude: 9°16′60′′N Longitude: 
79°17′60′′E) in December 2010 by collaborators at CSIR-
National Institute of Oceanography, India. 
• (II): Set of 157 analogues of the marine compounds clathrodin 
and oroidin, designed and synthesized by collaborators at the 
University of Ljubljana, Slovenia. 
• (III): Set of 12 synthetic compounds based on the 4,5,6,7-
tetrahydrobenzo[1,2-d]thiazole-2-amine structure, designed 
and synthesized by collaborators at the University of 
Ljubljana, Slovenia. 
Compound stock solutions were prepared in DMSO or ethanol and 
stored at -20° C.  
4.2 Reference compounds 
The antiviral agent 6-azauridine was used as reference compound 
in the CHIKV replicon screening. 6-azauridine was used also for assay 
validation and optimization prior to compound screening for both 
Rluc (luminescence) and EGFP (fluorescence) detection. 6-azauridine 
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exhibited dose-dependent inhibition during 48-hour treatment of 
cells, inhibiting the expression of the Rluc marker with an IC50-value 
of 2 µM. 6-azauridine was obtained from Sigma-Aldrich Co. (Saint 
Louis, MO, USA), and the compound stock solution was prepared in 
DMSO. 
Ribavirin obtained from Sigma-Aldrich Co. (Saint Louis, MO, 
USA) was used for optimization and validation of the HCV replicon 
assay and as antiviral control compound in the HCV replicon 
screening. Ribavirin stock solution was prepared in DMSO. In the 24-
hour experiment setting, ribavirin inhibited expression of the HCV 
replicon with an IC50-value of 110 µM. In the 48-hour experiment, 
ribavirin had an IC50-value of 64 µM. 
In cytotoxicity testing in CHIKV and HCV replicon cells, the 
cytotoxic agent polymyxin B (Sigma-Aldrich Co. Saint Louis, MO, 
USA) was used as control compound. Polymyxin B was also used for 
the validation and optimization of the cytotoxicity assays. Polymyxin 
B stock solutions were prepared in DMSO. In 24-hour treatment of 
HCV replicon cells, polymyxin B had a CC50-value of 7900 IU/ml and 
in 48-hour exposure of BHK-CHIKV-NCT cells to polymyxin B the 
CC50-value was 5900 IU/ml. 
The characterized Hsp90 inhibitor 17-DMAG was used as 
reference compound for Hsp90 inhibition in cell-based studies and 
MST. 17-DMAG was obtained from InvivoGen (San Diego, CA, USA). 
In the BHK-CHIKV-NCT cell line, the IC50-value of 17-DMAG was 0.14 
µM. The IC50-value in the HCV replicon cell line was 0.06 µM 
(exposure time 48 h). In MST experiments, the Kd for 17-DMAG was 
0.27 µM. The compound stocks of 17-DMAG were prepared in ethanol. 
4.3 Cell-based methods  
4.3.1 Cell lines and culture conditions  
A baby hamster kidney cell line (BHK-21) harboring a CHIKV 
replicon (BHK-CHIKV-NCT) was used in screening of potential 
CHIKV replication inhibitors. This CHIKV replicon cell line, provided 
and developed by Pohjala and co-workers142, continuously expresses 
two marker proteins, enhanced green fluorescent protein (EGFP) and 
Renilla luciferase (Rluc) along with the selection marker puromycin 
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acetyltransferase. EGFP and Rluc marker proteins can be used as 
optional indicators of viral replicon expression.  
The CHIKV replicon cells were cultured in high-glucose Dulbecco’s 
Modified Eagle’s Medium with L-glutamine supplemented with 7.5% 
fetal bovine serum, 2% tryptose-broth phosphate, 1 mM sodium 
pyruvate, 100 IU/ml penicillin, 100 μg/ml streptomycin and 5 μg/ml 
puromycin. The cells were maintained aseptically at 37 °C with 5% CO2 
and 95% humidity and subcultured three times a week. 
The cell line used for the screening of potential HCV inhibitors was 
a human liver cancer Huh-7 cell line expressing a subgenomic replicon 
of HCV genotype 1b when exposed to continuous geneticin 
selection.143 Similarly to the CHIKV replicon cell line, the HCV 
replicon cell line expresses a marker protein (firefly luciferase, Fluc) 
that enables convenient detection of viral replicon inhibition. The cell 
line was kindly provided by Prof. Ralf Bartenschlager (University of 
Heidelberg, Germany).  
The HCV replicon cell line was cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, 100 
IU/ml penicillin, 100 μg/ml streptomycin, 292 μg/ml L-glutamine, 1% 
non-essential amino acids, and 250 μg/ml geneticin. The cells line was 
maintained aseptically at 37 °C with 5% CO2 and 95% humidity and 
subcultured 2-3 times per week. 
4.3.2 Screening for CHIKV replication inhibitors 
For the CHIKV replicon inhibition assay (studies I and II), CHIKV 
replicon cells were seeded onto opaque-white, clear-bottomed 96-well 
plates (PerkinElmer Inc., Waltham, MA, USA). The cell-density used 
for the experiments was 40 000 cells/well. The plated cells were 
allowed to incubate for 24 hours at 37 °C.  
The studied samples (dissolved compounds and soft coral extracts 
and extract fractions) and were diluted into assay medium that 
consisted of high-glucose Dulbecco’s Modified Eagle’s Medium and L-
glutamine supplemented with 5% fetal bovine serum (FBS), 1 mM 
sodium pyruvate, 100 IU/ml penicillin and 100 μg/ml streptomycin. 
Each sample was tested in triplicate. Cells were exposed to compounds 
for 48 hours.  
After exposing the cells to compounds, the Rluc marker expression 
was determined with a Renilla luciferase assay kit from Promega 
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(Madison, WI, USA) following the manufacturer’s instructions. 
Varioskan Flash plate reader (Thermo Fischer Scientific, Vantaa, 
Finland) was used for luminescence detection. In the luminescence 
measurement, automatic dynamic range settings and a measurement 
time of 1 s was applied. In primary screening, each sample was tested 
in triplicate.  
4.3.3 Screening for HCV replication inhibitors 
For evaluation of HCV replicon inhibition in studies II and III, 
HCV replicon cells were seeded onto opaque-white, clear-bottomed 
96-well microplates from PerkinElmer Inc (Waltham, MA, USA) using 
a cell density of 30 000 cells/well. The cells were allowed to incubate 
overnight at 37°C before starting the experiment. 
Dissolved compounds were diluted in assay medium consisting of 
Dulbecco’s modified Eagle’s medium supplemented with 5% fetal 
bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, 292 
μg/ml L-glutamine and 1% non-essential amino acids.  Each 
compound was tested in triplicate.  
After exposure to compounds, the inhibition of the HCV replicon 
was measured by detection of the Fluc marker using a Luciferase 
Assay System kit from Promega Co. (Madison, WI, USA). In the 
primary screening of the compound library of clathrodin and oroidin 
analogues (study II), inhibition of the HCV replicon was evaluated 
after 24-hour exposure. In the next screening phases (studies II and 
III) a prolonged exposure time of 48 hours was applied. A Varioskan 
Flash plate reader (Thermo Fisher Scientific, Finland) was used for 
luminescence detection. In plate readings, automatic dynamic range 
settings and a measurement time of 1 s was utilized. 
4.3.4 Cytotoxicity evaluation 
The evaluation of compound cytotoxicity was performed in HCV 
and CHIKV replicon cell lines by ATP quantitation. The assay 
conditions, cell density and exposure time to compounds was the 
same as in the anti-replicon assays. Each compound was tested in 
triplicate. The composition of the assay medium used for HCV and 
CHIKV replicon cells is described in 4.3.2 and 4.3.3. Opaque-white, 
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clear-bottomed 96-well microplates (PerkinElmer Inc., Waltham, 
MA, USA) were used in all cytotoxicity assays.  
ATP quantitation was carried out using a CellTiter GLO® 
Luminescent Cell Viability Assay kit (Promega, Madison, WI, USA). 
After exposing the HCV or CHIKV replicon cells to compounds for 24 
or 48 hours, cells were allowed to equilibrate at room temperature, 
then washed with phosphate buffered saline solution before adding 50 
µl CellTiter GLO® Reagent and 50 µl assay medium to plate wells. Cell 
lysis was induced by shaking the plates for 2 minutes, and after 1o 
minutes at room temperature, the luminescence signal was recorded 
with a Varioskan Flash plate reader (Thermo Fisher Scientific, 
Finland) as described in sections 4.1.2 and 4.1.3. 
4.3.5 Live-cell imaging 
A continuous cell culturing platform (Cell-IQ® Fluorescence, 
Chip-Man Technologies Ltd., Tampere, Finland) was used in study I. 
This method enabled simultaneous analysis of cell proliferation, 
morphology and expression of EGFP marker in CHIKV replicon cells. 
Clear-bottomed, black-framed 96-well plates from PerkinElmer Inc. 
(Waltham, MA, USA) were used in the experiment. 3000 cells/well 
were seeded onto plates and incubated for 24 hours at 37 °C before 
adding the compounds diluted in assay medium (for composition see 
section 4.3.2). All assays were performed in triplicate.  
After exposing the cells to the compounds, the assay plate was 
equipped with a Cell-Secure Lid (Chip-Man Technologies, Tampere, 
Finland) with gas input connector and a sterile 0.2 μm filter.  The 
imaging study was carried out for 48 hours by taking phase-contrast 
and fluorescent images every 30 minutes using a 10× objective. 
Incubation was carried out at 37 °C using the equipment 
manufacturer’s default CO2 flow settings. In phase-contrast imaging, 
exposure time was 10 ms and z-stack 17.60 μm. In fluorescent 
imaging, the manufacturer’s default settings for green fluorescent 
protein with exposure time of 200 ms and binning 2 × 2 were used.  
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4.3.6 Data analysis and assay quality in cell-based 
experiments 
In the calculation of CHIKV and HCV replicon inhibition based on 
luminescent marker protein detection, the luminescence signal for 
DMSO vehicle in assay medium was used as maximum signal, to 
which the luminescence signal of cells treated with compounds was 
compared. The inhibition of viral replicon was expressed as 
percentage compared to the maximum signal. The cytotoxic effect of 
compounds expressed as a percentage was calculated by using the 
signal from cells treated with DMSO vehicle only as maximum signal 
and wells with reagent only as background value. 
In dose-response analyses, the dose-response data was fitted to 
sigmoidal dose-response curves by using the OriginPro 8.6 software 
(OriginLab, Northampton, MA, USA). Based on sigmoidal fitting, IC50 
and CC50-values were calculated using the software. Selectivity indices 
(SI) were obtained by dividing the CC50 with the IC50.  
Throughout the cell-based experiments based on luminescence 
detection, assay quality was monitored for each individual assay plate. 
The used quality parameters were signal-to-background ratio (S/B), 
signal-to-noise ratio (S/N) and screening window coefficient (Z’-
factor).144 
6-azauridine (Sigma-Aldrich Co., Saint Louis, MO, USA) was used 
as control compound for the assay optimization and validation of the 
live-cell imaging assay. The imaging results were analyzed using the 
Cell-IQ Analyser® software (Chip-Man Technologies, Tampere, 
Finland) by creating analysis protocols following instructions from the 
software supplier. The cell counting protocol was created and 
optimized by defining segmentation parameters and building a 
sample cell library allowing the software to automatically classify cells 
as living, dead or dividing based on the cell morphology. The 
fluorescence intensity protocol was created and optimized for the 
assay conditions by adjusting brightness, contrast, gamma, 
background correction and fluorescence threshold. The live-cell 
imaging assay and analysis protocols were validated by running 48-
hour tests for DMSO vehicle, control antiviral agent 6-azauridine and 
control cytotoxic agent polymyxin B. 
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4.4 Microscale thermophoresis 
Microscale thermophoresis (MST) was used to study compound 
binding to Hsp90. Full-length human Hsp90β (GenBank Accession 
No. AY359878) with C-terminal His tag) MW = 83 kDA, expressed in 
an E. coli expression system was obtained from Sigma- Aldrich Co. 
(Saint Louis, MO, USA). A Monolith NT™ Protein Labeling Kit RED-
NHS (NanoTemper Technologies GmbH, Munich, Germany) was 
used for Hsp90β labelling.  
The dilution series of test compounds (16 concentrations, 0.003 to 
100 µM) and control compound 17-DMAG (14 concentrations, 0.0015 
to 12.5 µM) dissolved in ethanol were prepared using a buffer 
containing 50 mM Tris–HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 
0.05% Tween-20 and 5% (V/V) ethanol. Three independent 
measurements were run for each compound.  
Compounds dissolved in buffer were mixed with labeled Hsp90β 
at a final concentration of 35 nM and transferred into Monolith NT.115 
premium- coated capillaries (NanoTemper Technologies GmbH). A 
NanoTemper Monolith NT.115 instrument (NanoTemper 
Technologies GmbH) was used for MST measurements using 20% 
LED power and 20% MST power. Analysis of the results and 
calculation of dissociation constants was performed by using the NT 
Analysis software (NanoTemper Technologies GmbH) based on 
thermophoresis and temperature jump data from the three separate 
measurements. 
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5 RESULTS  
This chapter summarizes the results of the original publications I-
III. Publication I describes the study of Indian Ocean soft coral 
Sinularia kavarattiensis. The starting point of the study of S. 
kavarattiensis was bioactivity testing of methanol and methanol-
chloroform extracts, followed by chemical fractionation and 
compound isolation. The isolated compounds’ antiviral potential and 
cytotoxic properties were evaluated in a CHIKV replicon cell model 
using luminescence-based detection techniques and live-cell imaging 
with integrated fluorescence detection.  
Publications II and III focused on exploring the antiviral potential 
of synthetic compounds that are based on a marine lead structure. 
Publication II covers the screening of a library of synthetic 
compounds inspired by alkaloid compound oroidin in CHIKV and 
HCV replicon models, along with the mode of action-studies based on 
the assumed target in the HCV replication cycle. Based on the results 
of study II and the assumed target protein, a series of novel synthetic 
compounds was designed. This compound series was studied for 
antiviral potential and potential mode of action against HCV (III).   
5.1 Antiviral, cytotoxic and anti-
inflammatory properties of S. 
kavarattiensis (I) 
5.1.1 Primary screening and bioactivity-guided 
fractionation  
The Indian Ocean soft coral S. kavarattiensis was studied as part 
of a larger bioactivity screening project and selected for further 
exploration due to promising results in the primary screening phase. 
The methanol extract of S. kavarattiensis decreased the level of Rluc 
marker in the BHK-CHIKV-NCT replicon cell line by 71%, whereas the 
methanol-chloroform extract decreased marker levels by 72%. Both 
extracts were tested at a 100 µg/ml concentration. In primary 
cytotoxicity testing, the methanol extract caused a 15% reduction in 
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ATP levels compared to the control, whereas a 17% reduction was 
observed for the methanol-chloroform extract. Both extracts inhibited 
the Rluc marker expression in a dose-dependent manner.  
Following the bioactivity studies on the crude extracts, a 
fractionation was performed for the methanol extract and the same 
bioactivity assays were performed for the obtained enriched extracts. 
The chloroform-enriched extract decreased Rluc marker levels by 47% 
and showed 24% cytotoxicity as measured by reduction in ATP levels 
at concentration 100 µg/ml. The ethyl acetate-enriched extract (100 
µg/ml) decreased Rluc marker levels by 65% and caused 20% 
reduction in ATP levels. The chloroform-enriched extract was selected 
for further fractionation, resulting in isolation of six known 
norcembranoid compounds 1-6 (I) and one new compound, 
kavaranolide (7, I). The chemical structures of compounds 1-7 (I) are 
shown in Figure 6. 
Figure 6.  Compound structures 1-7 (I). 
5.1.2 Primary evaluation and imaging studies of 
isolated compounds 
In the primary evaluation phase, isolated compounds 1-3 (I) and 
5-7 (I) were tested at a single 100 µM concentration for inhibition of 
the CHIKV replicon and cytotoxicity. The compounds caused an 
inhibition of the CHIKV replicon between 0.5% and 63% as shown by 
decrease of Rluc marker expression (Figure 7) and only slight 
cytotoxicity (<6%). Compounds 1 and 2 (I) showed the strongest 
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inhibition, with more than 60% reduction of Rluc marker expression 
compared to the vehicle control.  
 
Figure 7. CHIKV replicon inhibition of compounds 1-3 (I) and 
5-7 (I), determined by the measurement of Rluc 
marker after 48 h. Inhibition percentages are 
expressed as the average of three replicates. Error bars 
represent standard deviation. The positive control, 6-
azauridine, inhibited the replicon with an average IC50 
value of 2 μM. 
 
As follow-up, a live-cell imaging study with integrated 
fluorescence intensity measurement for the detection of EGFP marker 
protein was conducted for BHK-CHIKV-NCT cells treated for 48 h 
with compounds 1-3 (I) and 5-7 (I). The imaging study confirmed the 
results of the Rluc marker experiment, showing that compounds 1 and 
2 (I) decreased the fluorescence marker protein levels more than 
compounds 5, 6 and 7 (I), that caused only minor decrease of the 
fluorescence intensity (Figure 8).  The EGFP expression inhibition by 
compound 1 (I) was, however, not as prominent as the Rluc marker 
decrease observed previously. Likewise, compound 3 (I) did not 
decrease fluorescence intensity in the imaging experiment at the 
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tested concentrations 50 and 100 μM, despite that a 44% decrease of 
Rluc marker was observed by luminescence detection.  
 
 
Figure 8.  Inhibition of CHIKV replicon (%) and the cytotoxicity 
(%) of compounds 1-3 (I) and 5-7 (I) measured by Cell-
IQ® live cell imaging in the BHK-CHIKV-NCT cell line 
after 48 h exposure. Results are presented as the 
average of two independent assays with three 
replicates each; error bars represent standard 
deviation. 
 
An additional benefit of the imaging study was that it enabled a 
more thorough study of the compounds’ cytotoxic properties. Live-cell 
imaging revealed the cytotoxic properties of compounds 1 and 2 (I) 
that were not observed in the ATP quantitation experiment. In the 
imaging of cells treated with 100 μM of 1 and 2 (I), the number of cells 
classified as living or dividing decreased by >80%, even though the 
decrease of fluorescence intensity was not as dramatic. Figure 9 shows 
images of changes in morphology and expression of EGFP in cells 
treated with 50 μM and 100 μM of compounds 1-3 (I), 5-7 (I), 
control 6-azauridine and the vehicle DMSO captured after 48 h 
exposure.  
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Figure 9.  Photomicrographs captured using Cell-IQ® after 48 h 
exposure of BHK-CHIKV-NCT cells to 1-3 (I), 5-7 (I), 
control compound 6-azauridine and vehicle DMSO.  
 
The cell density used in experiments was hypothesized to be an 
underlying reason behind the observed cytotoxicity of compounds 1 
and 2 (I). To further study the impact of cell density, additional ATP 
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quantitation experiments were performed for compounds 1 and 2 (I) 
by using the same, lower, cell density (3000 cells/well) as in the 
imaging studies. These experiments showed that the cell density 
indeed plays a major role in the resistance to toxic effects of the 
compounds. At the lower cell density of 3000 cells/well, a 100 μM 
concentration of compounds 1 (I) and 2 (I) reduced ATP levels by 
39% and 44%, respectively. 
5.1.3 Anti-inflammatory and immunomodulatory 
activity of purified compounds 
The anti-inflammatory activity of compounds 1–4 and 6 (I) was 
evaluated in primary microglial cell cultures. In this study, compound 
2 (I) induced a shift from ameboid microglia to ramified microglia 
shapes, which indicates that 2 (I) shows potential to modulate the 
cellular immune response. In addition to the observed effect on cell 
morphology, decreased levels of pro-inflammatory cytokines IL-1β, 
IL-6, IL-8, IL-18 and TNF-α and increased levels of anti-inflammatory 
cytokines IL-4 and IL-10 were observed in cell cultures treated with 
2.5 μg/ml (7.2 μM) 5.0 μg/ml (14.4 μM) of compound 2 (I).  
Compound 2 (I) also effectively and dose-dependently inhibited 
cytokine release in dose-response experiments. The IC50-values for 
cytokine release inhibition ranged from 0.5 μg/ml to 2.9 μg/ml for the 
tested cytokines, being considerably lower than the corresponding 
values for the positive control prednisolone (IC50 range 10-20 μg/ml). 
The IC50-value for cytotoxic activity was higher than the maximum test 
concentration 100 μg/ml, thus cytotoxic effects did not impact the 
results. 
5.2 Antiviral potential of synthetic clathrodin 
and oroidin analogues and their 
derivatives (II, III) 
5.2.1 Primary evaluation, hit selection and 
optimization  
A library of 157 analogues of the marine compounds clathrodin 
and oroidin was screened for potential antiviral activity in BHK-
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CHIKV-NCT and HCV-Huh-7 replicon cell lines. The compound 
concentration in the initial testing was 50 µM. 15 compounds 
inhibited the Rluc marker expression in the CHIKV replicon cell line 
by more than 50% (hit rate 9.6%) and 30 compounds inhibited the 
Fluc marker expression in HCH-Huh-7 cells by more than 50% (hit 
rate 19%).  
The hit compounds from the primary screens were tested for 
cytotoxicity by ATP quantitation and the dose-response was evaluated 
in the viral replicon models. A majority of the primary hits were 
excluded in this phase because of toxic effects, lack of clear dose-
response correlation or lack of efficacy.  
Four compounds from the initial library (Figure 10) inhibited the 
HCV replicon marker expression in a dose-dependent manner with 
IC50-values ranging from 1.6 to 4.6 μM and selectivity indices in the 
range of 22 to 61. Out of the four hits, compound 2 (II) inhibited HCV 
replicon expression with the lowest IC50-value (1.6 μM) and highest 
selectivity (SI 60).  
Figure 10. Compound structures 1-4 (II). 
To achieve improved binding to Hsp90, a series of 12 new 
structurally optimized compounds was designed and synthesized 
based on compound 2 (II), which showed the highest potential for 
HCV inhibition in the initial series of clathrodin and oroidin 
analogues. In the novel series of compounds, the 2-amino group of the 
4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2-amine was substituted via 
amide bond with side chains containing heteroaromatics, amino 
groups, or carbamates for improved interaction with Hsp90 (Table 4). 
  47 
Table 4.  Compound structures 2-13 (III). 
 
Compound R 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
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9 
 
10 
 
11 
 
12 
 
13 
 
 
The 12 new compounds were initially screened in the HCV replicon 
cell model at a concentration of 50 µM. Based on the primary 
evaluation and initial cytotoxicity studies using ATP quantitation, 
compounds 2, 5, 6, 8, 10 and 11 (III) were selected for further 
assessment of dose-response and cytotoxicity. The selected 
compounds inhibited the HCV replicon dose-dependently without 
inducing toxic effects at replicon-inhibiting concentrations (Table 5). 
Compounds 2, 5 and 8 (III) were finally selected for further 
assessment, as they inhibited the HCV replicon selectively at low 
micromolar concentrations. Compound 5 (III) inhibited the HCV 
replicon marker expression with an IC50-value of 1.3 µM and 
possessed the highest selectivity (SI=98), showing clear improvement 
in selectivity compared to compound 2 (II) and thus proving the 
optimization strategy successful (for all bioactivity results, see Table 
5).  
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5.2.2 Mode-of-action studies 
Each hit compound 1-4 (II) from the primary screening of the full 
compound library had originally been designed to target the ATP-
binding site of bacterial DNA gyrase and shared the common 
structural feature of an unsubstituted 2-amino group on a 4,5,6,7-
tetrahydrobenzo[1,2-d]thiazole core and a hydrophobic moiety either 
as a substituted pyrrolamide or indolamide (Figure 10). As bacterial 
DNA gyrase and the cellular chaperone Hsp90 share a structurally 
similar ATP-binding pocket145, Hsp90 was considered a potential 
target for the compounds. 
The effect of a known Hsp90 inhibitor, 17-DMAG, was evaluated 
in the HCV-Huh-7 cell line to assess the effect of Hsp90 inhibition on 
the HCV replicon marker expression. In dose-response experiments, 
17-DMAG inhibited the expression of the HCV replicon with an IC50-
value of 0.06 μM, thus showing that HCV replicon inhibition caused 
by compounds 1-4 (II) could be associated with binding to Hsp90. 
To further evaluate Hsp90 as a target, the potential binding modes 
of compounds 1-4 (II) to Hsp90 were studied by molecular docking, 
which supported the possible interaction with this target. This 
potential mode of action was therefore studied by means of microscale 
thermophoresis (MST). The obtained Kd-values for the interaction of 
compounds 1-4 (II) with Hsp90 isoform β were in the range of 18-79 
μM (Table 5), thus confirming the possible interaction, which was, 
however, considerably weaker than that observed for the positive 
control 17-DMAG (Kd 0.27 μM). 
To assess the applied optimization strategy, the interaction of 
structurally optimized 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole 
derivatives with Hsp90β was also studied by MST. Based on the 
results of the HCV replicon (genotype 1b) screen, the binding 
properties of compounds 2, 5, 6, 8, 11 and 13 (III) were assessed. 
Compounds 8 and 13 (III) showed the strongest interaction with the 
assumed target protein, with Kd values of 14±2.4 µM and 12±1.9 µM 
and slightly improved binding compared to compounds 1-4 (II) 
(Table 5). 
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Table 5.  Bioactivity of compounds 1-4 (II) and 2, 5, 6, 8, 10, 
11, 13 (III) and control compound 17-DMAG in HCV 
replicon models, against full-length HCV (2, 5 and 8, 
III) and affinity to human Hsp90β of compounds 1-4 
(II) and 2, 5, 6, 8, 11, 13 (III) and 17-DMAG 
determined by MST. The IC50 and CC50 values are 
reported as average +/- standard deviation of two 
(genotype 2a) or three (genotype 1b, full-length virus 
assay) replicates. MST results are presented as 
dissociation constant Kd ± standard deviation based on 
three separate measurements.  
 
Compound IC50 
HCV 
geno-
type 1b 
(µM) 
CC50 
HCV 
geno-
type 1b 
(µM) 
SI 
geno-
type 1b 
IC50 
HCV 
genoty
pe 2a 
(µM) 
IC50 
full-
length 
HCV 
(µM) 
Kd 
Hsp90 
(µM) 
1 (II) 4.6 ± 
0.43 
101 ± 
7.9 
22 nd nd 19 ± 5.7 
2 (II) 1.6 ± 
0.08 
98 ± 8.7 61 nd nd 39 ± 14 
3 (II) 3.1 ± 0.
8 
84 ± 1.8 27 nd nd 79 ± 17 
4 (II) 2.8 ± 
0.35 
78 ± 4.0 28 nd nd 18 ± 3.4 
2 (III) 2.5 ± 
0.25 
154 ± 
2.9 
62 1.52 ± 
0.15 
0.60 ± 
0.1 
28 ± 5.0 
5 (III) 1.3 ± 
0.23 
128 ± 
6.6 
98 0.49 ± 
0.06 
0.03 ± 
0.006 
16 ± 5.1 
6 (III) 22 ± 2.8 67 ± 2.0 3.0 nd nd 27 ± 2.2 
8 (III) 1.2 ± 
0.41 
48 ± 2.5 40 1.32 ± 
0.1 
0.10 ± 
0.02 
14 ± 2.4 
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Compound IC50 
HCV 
geno-
type 1b 
(µM) 
CC50 
HCV 
geno-
type 1b 
(µM) 
SI 
geno-
type 1b 
IC50 
HCV 
genoty
pe 2a 
(µM) 
IC50 
full-
length 
HCV 
(µM) 
Kd 
Hsp90 
(µM) 
10 (III) 5.5 ± 1.8 204 ± 
4.9 
37 nd nd nd 
11 (III) 21 ± 2.2 86 ± 5.2 4.1 nd nd 40 ± 4.9 
13 (III) 7.2 ± 
0.46 
72 ± 4.2 10 nd nd 12 ± 1.9 
17-DMAG 0.06 ± 
0.01 
1.7 ± 
0.25 
28 0.04 ± 
0.006 
* 0.27 ± 
0.02  
nd = not determined 
* no effect in the tested concentration range (IC50>5 μm) or time frame 
5.2.3 Antiviral activity against full-length HCV 
Compounds 2, 5 and 8 (III) were selected as the most promising 
HCV inhibitor candidates for further evaluation based on the highest 
selectivity and lowest IC50-values in the HCV genotype 1b replicon 
studies. These compounds were tested for antiviral activity against 
HCV by using a method based on the electroporation of full-length 
reporter virus RNA into Huh7 Lunet cells.  
As replicating full-length reporter viruses are derived from HCV 
genotype 2a, the compounds were first evaluated in a HCV genotype 
2a replicon cell line, similarly to the HCV replicon genotype 1b 
evaluation. Based on determination of IC50-values of the test 
compounds and the 17-DMAG control, HCV genotype 2a turned out 
to be equally susceptible to Hsp90 inhibition as genotype 1b. 
Compounds 2, 5 and 8 (III) inhibited the HCV genotype 2a replicon 
with IC50-values of 1.52 µM, 0.49 µM and 1.32 µM, respectively. Also, 
the 17-DMAG control was equally effective against genotype 2a (IC50 
= 0.04 µM).  
All three compounds 2, 5 and 8 (III) were also effective in the full-
length reporter virus assay. Compound 5 (III) had the lowest IC50-
value of 0.03 µM, whereas the IC50-values for 8 and 2 (III) were 0.05 
  52 
µM and 0.6 µM, respectively (Table 5). On the contrary, 17-DMAG did 
not inhibit the replication of the full-length virus in the tested 
concentration range and time frame. In a study by Kim and 
colleagues146 Huh7 cells infected with cell‐culture‐generated HCV 
genotype 2a (clone JFH1) were treated with 17-DMAG for 72 hours. In 
their study, 17-DMAG decreased HCV RNA levels with an IC50 value 
of 0.071 μM. In our experimental setting, the exposure time to the 
compounds was only 24 hours, which might be a reason underlying 
the lack of efficiency of 17-DMAG. 
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6 DISCUSSION 
The studies I-III cover two different approaches to marine drug 
discovery. On one hand, we studied a marine soft coral extract, which 
led to bioassay-guided fractionation, compound purification and 
bioactivity studies of the purified compounds. On the other hand, we 
utilized an approach based on bioactivity screening of a synthetic 
compound library inspired by marine structures, followed by chemical 
optimization of one of the hit compounds.  
In both of these approaches, the aim was the discovery of potential 
new antiviral agents. Reflecting the results towards this goal, study I 
led to the discovery of crude extracts and enriched fractions of S. 
kavarattiensis with promising activity in the CHIKV replicon cell line, 
but the study of purified compounds showed cytotoxic effects and lack 
of specificity, leading to the conclusion that the compounds would 
likely not be of interest as potential antivirals. The modest activity of 
purified compounds in a specific bioactivity assay compared to the 
promising activity observed for extracts is a well-known phenomenon 
in natural product drug research.147   
Natural product extracts are mixtures of hundreds, or sometimes 
thousands, of individual chemical constituents at different 
concentrations, and it is frequently challenging to assign the activity 
of an extract to one or few compounds in the mixture.148 The reason 
behind the higher biological activity of extracts is often claimed to be 
the beneficial synergistic interactions of the compounds in the 
mixture. Also antagonism, where the effects of one active constituent 
in a mixture are masked by another component, can affect the 
bioactivity studies of mixtures, which constitutes another challenge to 
natural product-based drug discovery.147     
In the study of marine bioactive compounds derived directly from 
the marine source organism, such as the work described in publication 
I, supply issues must be carefully considered. Various strategies can 
be applied to overcome supply challenges, ranging from compound 
isolation from the source organism to utilizing microbial metabolites 
and applying total synthesis.149 Both for ecological and economic 
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reasons it is oftentimes favorable to explore the potential synthetic 
routes instead of collecting and processing the source organism.  
Despite the drawback of not identifying remarkable antiviral 
activity for any of the purified compounds of S. kavarattiensis, one 
previously undescribed compound, kavaranolide, was identified in 
study I, and compound 2 (I) was shown to possess promising anti-
inflammatory and immunomodulatory potential. Thus, the results 
contributed to a better understanding of the soft coral species S. 
kavarattiensis and its bioactive potential. The results also highlight 
the importance of early cytotoxicity-profiling of studied extracts and 
isolated compounds. Taking into consideration that the plethora of 
marine diversity to date is only partly explored, numerous 
opportunities remain to discover potent bioactive compounds through 
exploration of natural resources.  
Studies II and III on synthetic analogues of marine natural 
products enabled the exploration of the individual compounds for 
which the chemical structure responsible for the observed bioactivity 
was known. Furthermore, the structure-activity relationships could be 
studied, and chemical optimization opened new pathways to improve 
the bioactivity. The study of synthetically obtained marine compounds 
or their derivatives as exemplified in publications II and III is, unlike 
the study of compounds isolated from the marine source organism, 
not limited by sufficient compound supply or challenges in the 
sustainable exploitation of natural resources.  
From a methodological point of view, studies I to III include a 
selection of methods well-adapted for the study of potential antiviral 
properties of diverse compound libraries.  Each of these studies also 
demonstrate the strength of a close multiprofessional collaboration 
that covers chemical characterization and synthesis combined to 
bioactivity profiling. In studies I to III, knowledge of the compound 
chemistry that was brought to each project through close 
collaboration with scientists experienced in chemical synthesis and 
analytics enabled coherent directing and planning of the bioactivity 
assays. 
Replicon-based screening approaches are an excellent tool for 
primary study of potential viral replication inhibitors, as they are safe, 
user-friendly and easily adaptable to a multiwell-plate format. 
Replicon-based screening methods, similar to those described in this 
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work, have been used in antiviral screening against various other 
human pathogens, such as Dengue virus and West Nile virus.150,151 In 
replicon-based screening methods, fluorescent and luminescent 
proteins are often used as markers, as they enable efficient and robust 
result detection. While being accessible and convenient, the viral 
replicon-harboring cell lines are limited in terms of correspondence to 
all aspects of the clinical virus infection, as inhibitors of the entry and 
maturation phases in the viral life cycle cannot be identified by using 
this method. 
Study II resulted in the identification of hit compounds with 
selective activity and low micromolar IC50-values in the HCV replicon 
model. Compound 2 (II), which inhibited the HCV replicon 
expression with the lowest IC50-value (1.6 μM) and highest selectivity 
(SI 60) was selected as the lead compound for further structural 
optimization, which resulted in the synthesis of 12 new compounds 
bearing the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole structure. The 
optimization strategy turned out to be successful considering the 
improved selectivity (SI 98) of compound 5 (III) compared to the lead 
compound (2 [II], SI 60). The low cytotoxicity of compound 2 (II) 
derivatives is especially outstanding when comparing to the reference 
compound 17-DMAG.  Compounds 2 (III) and 5 (III) did not show 
cytotoxic effects at replicon-inhibiting concentrations in the HCV 
genotype 1b replicon cells (CC50 values >100 μM), whereas the CC50 
value for the reference compound 17-DMAG was 1.7 μM with a 
selectivity index of 28. 
The structural optimization of compound 2 (II) did not result in 
major improvement in the affinity to the assumed target protein 
Hsp90. The binding affinity of the positive control 17‐DMAG to Hsp90 
was approximately 50-fold to that of compounds 8 and 13 (III), which 
were the compound 2 (II) derivatives with the strongest affinity to 
Hsp90. There is also no clear correlation between the replicon-
inhibiting activity and affinity to Hsp90 of the studied compounds 1-
4 (II) and 2, 5, 6, 8, 10, 11 and 13 (III).  Therefore, it is possible that, 
in addition to Hsp90, there are other cellular targets underlying the 
activity. This could also contribute to explaining why the control 
Hsp90 inhibitor 17-DMAG was active in the HCV replicon assays, but 
inactive in the full-length reporter virus assay.  
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Hsp90 plays several roles in the HCV and CHIKV lifecycles. Hsp90 
enables HCV replication through interaction with two viral non-
structural proteins, NS3 and NS5129-135 and impacts the expression of 
viral genes through interaction with argonaute2, a host cell protein.136 
CHIKV nsP3 and nsP4 are probable Hsp90 client proteins and Hsp90 
inhibitors reduce viral titres and inflammation in vivo. 137 Hsp90 also 
interacts with CHIKV nsP2, and the translation of viral and cellular 
mRNA may be facilitated through a Hsp90-associated signaling 
pathway.138 Inhibiting the function of Hsp90 thus interferes with 
several aspects of the progression of HCV and CHIKV infection in the 
host cell. 
Targeting host factors such as Hsp90 in antiviral drug 
development could be an advantageous strategy in combatting drug‐
resistant viral strains. Because of the multiple roles of Hsp90 in the 
cellular life cycle, the foremost challenge in the clinical development 
of Hsp90 inhibitors is the in vivo toxicity related to the off-target 
effects and challenges with target specificity, resulting in the failure 
and termination of many Hsp90 inhibitor‐associated clinical trials.141 
Study III demonstrated that compounds 2 (III) and 5 (III) did not 
show considerable cytotoxicity in vitro. These results are especially 
encouraging when comparing compounds 2 (III) and 5 (III) to the 
reference Hsp90 inhibitor 17‐DMAG, which is potent, but also 
cytotoxic at low concentrations, indicating a narrow therapeutic 
window.  
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7 CONCLUSIONS AND FUTURE 
PROSPECTS 
The main findings of the work presented herein are: 
1. The results of study I contributed to a deeper understanding 
of the chemical constituents and bioactive properties of soft 
coral species S. kavarattiensis. The live-cell imaging -based 
method developed and used in the study enabled concurrent 
analysis of the compounds’ inhibition of the CHIKV replicon 
and effects on cell morphology and proliferation. 
 
2. Bioactivity screening of a library of synthetic clathrodin and 
oroidin analogues led to the identification of four hit 
compounds with potent and selective activity in a HCV 
replicon model (II). The study of the assumed mechanism of 
action resulted in the synthesis of a targeted set of 12 novel 
compounds based on the 4,5,6,7-tetrahydrobenzo[1,2-
d]thiazole structure (III). Improved selectivity in the HCV 
replicon genotype 1b model and slightly improved binding to 
the proposed target protein Hsp90 was observed, showing that 
the selected optimization strategy was successful. 
Furthermore, three compounds were shown to specifically 
inhibit the replication of full-length HCV genotype 2a in a 
reporter virus RNA assay. 
 
In conclusion, this thesis shows substantial examples of two 
different approaches to marine drug discovery: a bioactivity study of 
marine extracts followed by the isolation and bioactivity studies of 
purified compounds, and a marine lead compound-based synthetic 
approach covering chemical optimization of identified hit compounds 
and study of the plausible mechanism of action. 
A broader knowledge of the role of Hsp90 in the replication and 
infectivity of viruses is vital for achieving success in antiviral Hsp90 
inhibitor development. Improved insight into the intricate role played 
by Hsp90‐type proteins in the cellular life cycle is the key for tackling 
the issues faced with off‐target effects and lack of specificity that have 
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hampered the clinical development of Hsp90 inhibitors. The results 
of publications II and III imply that Hsp90 is a potential target of the 
studied compounds and can guide further development of antiviral 
agents targeting this cellular protein. 
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